Follow
Jonathan Stutters
Jonathan Stutters
Verified email at ucl.ac.uk
Title
Cited by
Cited by
Year
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
J Chataway, F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, ...
The Lancet Neurology 19 (3), 214-225, 2020
1152020
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
HP Hartung, T Derfuss, BAC Cree, MP Sormani, K Selmaj, J Stutters, ...
Multiple Sclerosis Journal 28 (3), 429-440, 2022
602022
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, ...
The Lancet Neurology 20 (9), 709-720, 2021
602021
Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing …
P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John, ...
BMJ open 8 (8), e021944, 2018
542018
Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis
A Calvi, FP Carrasco, C Tur, DT Chard, J Stutters, F De Angelis, N John, ...
Neurology 98 (17), e1783-e1793, 2022
442022
A brain-derived metric for preferred kinetic stimuli
S Zeki, J Stutters
Open biology 2 (2), 120001, 2012
412012
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
E Colato, J Stutters, C Tur, S Narayanan, DL Arnold, ...
Journal of Neurology, Neurosurgery & Psychiatry 92 (9), 995-1006, 2021
392021
Functional specialization and generalization for grouping of stimuli based on colour and motion
S Zeki, J Stutters
Neuroimage 73, 156-166, 2013
392013
Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis
A Calvi, C Tur, D Chard, J Stutters, O Ciccarelli, R Cortese, M Battaglini, ...
NeuroImage: Clinical 35, 103048, 2022
262022
Colournamer, a synthetic observer for colour communication
D Mylonas, J Stutters, V Doval, L MacDonald
NewcastleGateshead Convention Bureau, 2013
202013
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, N John, ...
Efficacy and Mechanism Evaluation 7 (3), 1-72, 2020
162020
NAA is a marker of disability in secondary-progressive MS: A proton MR spectroscopic imaging study
BS Solanky, NA John, F DeAngelis, J Stutters, F Prados, T Schneider, ...
American Journal of Neuroradiology 41 (12), 2209-2218, 2020
152020
Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS)
Ö Yaldizli, D MacManus, J Stutters, DA Häring, F Lublin, MS Freedman, ...
MULTIPLE SCLEROSIS JOURNAL 21, 30-31, 2015
132015
Remyelination varies between and within lesions in multiple sclerosis following bexarotene
JWL Brown, F Prados, DR Altmann, B Kanber, J Stutters, NG Cunniffe, ...
Annals of clinical and translational neurology 9 (10), 1626-1642, 2022
82022
MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in …
J Chataway, F De Angelis, P Connick, R Parker, D Plantone, A Doshi, ...
MULTIPLE SCLEROSIS JOURNAL 24, 986-987, 2018
52018
Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis
A Calvi, Z Mendelsohn, W Hamed, D Chard, C Tur, J Stutters, ...
European journal of neurology 31 (1), e16092, 2024
42024
Networks of microstructural damage predict disability in multiple sclerosis
E Colato, F Prados, J Stutters, A Bianchi, S Narayanan, DL Arnold, ...
Journal of Neurology, Neurosurgery & Psychiatry 94 (12), 992-1003, 2023
42023
Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis
J Brown, N Cunniffe, F Prados, B Kanber, J Jones, E Needham, ...
MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 43-44, 2020
32020
LB01. 02-Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis
W Brown, N Cunniffe, F Prados
MSVirtual2020 (formerly 8th Joint Meeting ACTRIMS-ECTRIMS Annual Congress), 2020
32020
Longitudinal metabolite changes in progressive multiple sclerosis: a study of 3 potential neuroprotective treatments
NA John, BS Solanky, F De Angelis, RA Parker, CJ Weir, J Stutters, ...
Journal of Magnetic Resonance Imaging 59 (6), 2192-2201, 2024
22024
The system can't perform the operation now. Try again later.
Articles 1–20